title: [Four cutaneous leishmaniosis case resistant to meglumine antimoniate treatment].
abstract: OBJECTIVE
  The aim of the study was to treatment of cutaneous leishmaniasis caused by meglumine antimoniate resistant Leishmania major with Lucilia sericata larvae.
  
  
  METHODS
  Samples obtained from patients'lesions were stained with Giemsa and examined under the microscope. The samples were also incubated to Novy-Nicolle-McNeal (NNN) and Roswell Park Memorial Institute (RPMI) 1640 media. ITS1 region real time PCR was performed for identfying the Leishmania species. The patients were treated using Glucantime® or liposomal amphotericin B or L. sericata larvae according to their response to the treatmet regimes.
  
  
  RESULTS
  In the initial examination, amastigote forms of Leishmania were seen in the samples of all 4 patients under microscopic examination. Two of the patients with cutaneous leishmaniasis, which were caused by Glucantime resistant L. major were treated with liposomal amphotericin B, and two of them were treated with L. sericata larvae. Leishmania promastigotes were not grown in both cultures.
  
  
  CONCLUSIONS
  Cutaneous leishmaniasis, which wascaused by Glucantime resistant L. major has been successfully treated with L. sericata larvae in a very short time, 10 days. PCR results from samples taken 2 months after the treatment were examined and the results were negative.
authors.affiliation: İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, İstanbul, Türkiye. erdalp@istanbul.edu.tr.
authors.forename: Erdal
authors.initials: E
authors.lastname: Polat
authors.forename: Zekayi
authors.initials: Z
authors.lastname: Kutlubay
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D021901:DNA, Intergenic / Q000302:isolation & purification; D016054:DNA, Protozoan / Q000302:isolation & purification; D004175:Diptera / Q000502:physiology*; D004351:Drug Resistance; D006801:Humans; D007814:Larva; D007891:Leishmania; D018320:Leishmania major / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D016773:Leishmaniasis, Cutaneous / Q000469:parasitology / Q000628:therapy*; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D021901:DNA, Intergenic; D016054:DNA, Protozoan; D009942:Organometallic Compounds; C068538:liposomal amphotericin B; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B